Novo Nordisk’s oral Wegovy reaches 3 million prescriptions, outpacing its injectable version amid strong demand in the GLP-1 market.
Novo Nordisk’s Wegovy pill has surpassed 3 million prescriptions, accelerating faster than its injectable predecessor. The oral version addresses consumer preference for non-injectable treatments, bolstering the company’s position in the competitive GLP-1 market.
The injectable Wegovy initially faced supply constraints, allowing rival Eli Lilly’s Mounjaro and Zepbound to gain traction. Despite this, Novo Nordisk’s first-mover advantage with the pill has driven rapid adoption, signaling strong demand for obesity and diabetes treatments.
The GLP-1 market remains dominated by Novo Nordisk and Eli Lilly, with oral formulations emerging as a key growth driver. Analysts are closely watching prescription trends as competition intensifies.